17 research outputs found
Recommended from our members
IN-SITU RADIONUCLIDE TRANSPORT NEAR THE NOPAL I URANIUM DEPOSIT AT PENA BLANCA, MEXICO: CONSTRAINTS FROM SHORT-LIVED DECAY-SERIES RADIONUCLIDES
For nuclear waste management, an important mechanism by which radioactive waste components are isolated from returning to the human environment, the biosphere, is by the geological barrier in which the effectiveness of the barrier is characterized by in-situ retardation factor, i.e., the transport rate of a radionuclide relative to that of groundwater. As part of natural analog studies of the Yucca Mountain Project of the U. S. Department of Energy, we propose such characterization by using naturally-occurring decay-series radioisotopes as an analog. We collected large-volume (>1000 liters) groundwater samples from three wells (PB, Pozos, and PB4, respectively) near the Nopal I Uranium Ore site at Pena Blanca, Mexico, by using an in-situ Mn-cartridge filtration technique for analysis of short-lived decay-series radionuclides. Results show that the activities of short-lived radioisotopes ({sup 228}Ra, {sup 224}Ra and {sup 223}Ra) and activity ratios of {sup 224}Ra/{sup 228}Ra and {sup 224}Ra/{sup 223}Ra are higher at PB and Pozos than at PB4. In contrast, the {sup 210}Po activity is much lower at PB and Pozos than at PB4. The high Ra activities and activities ratios at PB and Pozos are attributable to the high alpha-recoil input from the aquifer rocks, while the high {sup 210}Po activity at PB4 is due to the enhanced colloidal transport. Based on a uranium-series transport model, we estimate that the in-situ retardation factor of Ra is (0.43 {+-} 0.02) x 10{sup 3} at PB, (1.68 {+-} 0.08) x 10{sup 3} at Pozos, and (1.19 {+-} 0.08) x 10{sup 3} at PB4 and that the mean fracture width in the aquifer rocks is about 0.23 {micro}m at PB, 0.37 {micro}m at Posos, and 4.0 {micro}m at PB4, respectively. The large fracture width at PB4 as derived from the model provides an additional evidence to the inference from the Po measurements that particle-reactive radionuclides are transported mainly as colloidal forms through the large fractures in rocks. Our model also suggests that in addition to alpha recoil, decay of {sup 226}Ra from the adsorbed phases also contributes a significant source of {sup 222}Rn to groundwater. It appears that the information obtained from this study provides useful testing and validation for the Yucca Mountain total system performance assessment model (TSPA)
An approximate mixed integer linear programming (MILP) model for the design of water reuse/recycle networks with minimum emergy
Recent trends in process engineering have placed increased emphasis on the design of inherently clean and efficient processes. For example, a wide range of pinch analysis and mathematical programming methods have been developed for designing schemes for water reuse/recycle in industrial plants for both grassroot design and plant retrofit. In the latter case, the conventional approach is to maximize water recovery and thereby minimize fresh water demand and effluent volume. However, it is possible that with such an approach the reductions in environmental impact brought about by saving water can be offset by other impacts arising from increased use of energy and materials in the plant after retrofit. This work presents a model for minimizing the total resource consumption impact of a water reuse/recycle network. The total impact is expressed in terms of emergy - a measure of cumulative solar energy inputs into a life cycle system. A simplified model is proposed that focuses on the impact contributions of water, electrical power and material for capital goods. Two case studies illustrate the approach. Results show that the network with the lowest total impact can be found by sacrificing water recovery for savings in energy and material use. © 2007 Curtin University of Technology and John Wiley & Sons, Ltd
Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial
IMPORTANCE Low-molecular-weight heparin is recommended over warfarin for the treatment of acute venous thromboembolism (VTE) in patients with active cancer largely based on results of a single, large trial.
OBJECTIVE To study the efficacy and safety of tinzaparin vs warfarin for treatment of acute, symptomatic VTE in patients with active cancer.
DESIGN, SETTINGS, AND PARTICIPANTS A randomized, open-label study with blinded central adjudication of study outcomes enrolled patients in 164 centers in Asia, Africa, Europe, and North, Central, and South America between August 2010 and November 2013. Adult patients with active cancer (defined as histologic diagnosis of cancer and receiving anticancer therapy or diagnosed with, or received such therapy, within the previous 6 months) and objectively documented proximal deep vein thrombosis (DVT) or pulmonary embolism, with a life expectancy greater than 6 months and without contraindications for anticoagulation, were followed up for 180 days and for 30 days after the last study medication dose for collection of safety data.
INTERVENTIONS Tinzaparin (175 IU/kg) once daily for 6 months vs conventional therapy with tinzaparin (175 IU/kg) once daily for 5 to 10 days followed by warfarin at a dose adjusted to maintain the international normalized ratio within the therapeutic range (2.0-3.0) for 6 months.
MAIN OUTCOMES AND MEASURES Primary efficacy outcome was a composite of centrally adjudicated recurrent DVT, fatal or nonfatal pulmonary embolism, and incidental VTE. Safety outcomes included major bleeding, clinically relevant nonmajor bleeding, and overall mortality.
RESULTS Nine hundred patients were randomized and included in intention-to-treat efficacy and safety analyses. Recurrent VTE occurred in 31 of 449 patients treated with tinzaparin and 45 of 451 patients treated with warfarin (6-month cumulative incidence, 7.2% for tinzaparin vs 10.5% for warfarin; hazard ratio [HR], 0.65 [95% CI, 0.41-1.03]; P = .07). There were no differences in major bleeding (12 patients for tinzaparin vs 11 patients for warfarin; HR, 0.89 [95% CI, 0.40-1.99]; P = .77) or overall mortality (150 patients for tinzaparin vs 138 patients for warfarin; HR, 1.08 [95% CI, 0.85-1.36]; P = .54). A significant reduction in clinically relevant nonmajor bleeding was observed with tinzaparin (49 of 449 patients for tinzaparin vs 69 of 451 patients for warfarin; HR, 0.58 [95% CI, 0.40-0.84]; P = .004).
CONCLUSIONS AND RELEVANCE Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding. Further studies are needed to assess whether the efficacy outcomes would be different in patients at higher risk of recurrent VTE